Review Note
Last Update: 03/31/2024 12:08 AM
Current Deck: Collab4PG
Published
Fields:
Text
{{c1::Rifampicin }} is the least likely main TB drug to require dose modification in renal failure patients
Back Extra
as it is metabolized in the liver and primarily excreted in bile.
This is a controversial question. Upon thorough review, we found that both rifampicin and isoniazid do not require dose adjustment. However, rifampicin would be the single best answer as it has a safer profile in CKD patients.
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: